Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

被引：0

作者：

Borghaei, H. ^{[1
]}

Langer, C. J. ^{[2
]}

Gadgeel, S. ^{[3
]}

Papadimitrakopoulou, V. A. ^{[4
]}

Patnaik, A. ^{[5
]}

Powell, S. F. ^{[6
]}

Gentzler, R. D. ^{[7
]}

Martins, R. G. ^{[8
]}

Stevenson, J. P. ^{[9
]}

Jalal, S. I. ^{[10
]}

Panwalkar, A. ^{[11
]}

Yang, J. C-H. ^{[12
]}

Gubens, M. ^{[13
]}

Sequist, L. ^{[14
]}

Awad, M. M. ^{[15
]}

Fiore, J. ^{[16
]}

Saraf, S. ^{[16
]}

Raftopoulos, H. ^{[16
]}

Gandhi, L. ^{[17
]}

机构：

[1] Fox Chase Canc Ctr, Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[2] Abramson Canc Ctr, Dept Med, Philadelphia, PA USA

[3] Karmanos Canc Inst, Thorac Oncol, Detroit, MI USA

[4] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Oncol, Houston, TX 77030 USA

[5] South Texas Accelerated Res Therapeut, Clin Res, San Antonio, TX USA

[6] Sanford Heath, Oncol, Sioux Falls, SD USA

[7] Univ Virginia, Hematol Oncol, Charlottesville, VA USA

[8] Univ Washington, Med, Seattle, WA 98195 USA

[9] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[10] Indiana Univ Sch Med, Internal Med, Indianapolis, IN 46202 USA

[11] Sanford Roger Maris Canc Ctr, Hematol Oncol, Fargo, ND USA

[12] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[13] Univ Calif San Francisco, Med Oncol, San Francisco, CA 94143 USA

[14] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA

[15] Dana Farber Canc Inst, Thorac Oncol, Boston, MA 02115 USA

[16] Merck & Co Inc, Clin Res, Kenilworth, NJ USA

[17] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA49

引用

页数：2

共 50 条

[31] First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
McDermott, David F.
Lee, Jae-Lyun
Ziobro, Marek
Gafanov, Rustem Airatovich
Matveev, Vsevolod Borisovich
Suarez, Cristina
Donskov, Frede
Pouliot, Frederic
Alekseev, Boris Y.
Wiechno, Pawel
Tomczak, Piotr
Duran, Miguel Angel Climent
Shin, Sang Joon
Silverman, Rachel Kloss
Perini, Rodolfo F.
Schloss, Charles
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[32] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
Hall, Richard Delmar
Gadgeel, Shirish M.
Garon, Edward B.
Bria, Emilio
Reck, Martin
Vida, John
Zhou, Honghong
Raftopoulos, Harry
Gandhi, Leena
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC)
Belani, Chandra Prakash
Yamamoto, Nobuyuki
Bondarenko, Igor
Orlov, Sergey V.
Tang, Jie
Niethammer, Andreas G.
Ingrosso, Antonella
Kim, Sinil
Scagliotti, Giorgio
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[34] Primary results from the China cohort of IMpower132: Atezolizumab (atezo) plus carboplatin (carbo) or cisplatin (cis) plus pemetrexed (pem) as first-line therapy in advanced NSCLC
Lu, S.
Fang, J.
Wang, Z.
Fan, Y.
Liu, Y.
He, J.
Cao, B.
Zhou, J.
Hu, J.
Xia, J.
Liu, W.
Shi, J.
Yi, J.
Cao, L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S753
[35] A randomized phase II trial comparing continuation maintenance therapy with pemetrexed and switch maintenance therapy with docetaxel after first-line therapy with carboplatin and pemetrexed in patients with advanced nonsquamous non-small cell lung cancer.
Karayama, Masato
Inui, Naoki
Kuroishi, Shigeki
Yokomura, Koshi
Toyoshima, Mikio
Shirai, Toshihiro
Masuda, Msafumi
Yamada, Takashi
Yasuda, Kazumasa
Suda, Takafumi
Chida, Kingo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[36] First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
O'Donnell, Peter H.
Balar, Arjun Vasant
Vuky, Jacqueline
Castellano, Daniel
Bellmunt, Joaquim
Powles, Thomas
Bajorin, Dean F.
Grivas, Petros
Hahn, Noah M.
Plimack, Elizabeth R.
Xu, Jin Zhi
Godwin, James Luke
Moreno, Blanca Homet
De Wit, Ronald
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[37] Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A
McDermott, D. F.
Lee, J-L.
Bjarnason, G. A.
Larkin, J.
Gafanov, R.
Kochenderfer, M. D.
Jensen, N. V.
Donskov, F.
Malik, J.
Poprach, A.
Tykodi, S. S.
Alonso-Gordoa, T.
Cho, D. C.
Geertsen, P. F.
Climent Duran, M. A.
Di Simone, C.
Liu, H.
Burgents, J.
Rodriguez-Lopez, K.
Atkins, M. B.
ANNALS OF ONCOLOGY, 2021, 32 : S691 - S692
[38] Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study
Cohen, Graham
Rapoport, Bernardo
Chan, Sze W.
Ruff, Paul
Arance, Ana
Eizmendi, Karmele Mujika
Houghton, Baerin
Brown, Michael P.
Zielinski, Robert M.
Couselo, Eva Munoz
Lyle, Megan
Anderson, James R.
Jain, Lokesh
de Alwis, Dinesh
Lala, Mallika
Akala, Omobolaji
Chartash, Elliot
Jacobs, Conrad
PLOS ONE, 2024, 19 (11):
[39] Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
Yang, Yunpeng
Sun, Jiya
Wang, Zhehai
Fang, Jian
Yu, Qitao
Han, Baohui
Cang, Shundong
Chen, Gongyan
Mei, Xiaodong
Yang, Zhixiong
Ma, Rui
Bi, Minghong
Ren, Xiubao
Zhou, Jianying
Li, Baolan
Song, Yong
Feng, Jifeng
Li, Juan
He, Zhiyong
Zhou, Rui
Li, Weimin
Lu, You
Zhou, Hui
Wang, Shuyan
Sun, Luyao
Puig, Oscar
Mancao, Christoph
Peng, Bo
Fang, Wenfeng
Xu, Wei
Zhang, Li
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2109 - 2120
[40] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
Shah, Manish A.
Sun, Jong-Mu
Shen, Lin
Kato, Ken
Enzinger, Peter C.
Adenis, Antoine
Doi, Toshihiko
Kojima, Takashi
Li, Zhigang
Kim, Sung-Bae
Cho, Byoung Chul
Mansoor, Wasat
Li, Shau-Hsuan
Sunpaweravong, Patrapim
Maqueda, Maria Alsina
Buchschacher, Gary L.
Wu, Jimin
Shah, Sukrut
Bhagia, Pooja
Metges, Jean-Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 250 - 250

← 1 2 3 4 5 →